Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP: Single-dose rtPA for Pulmonary Embolism
NCT03966079Phase 3Completed
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tissue-plasminogen activator in pulmonary embolism (PE), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Change of RV to LV Diameter Ratio at 30 days. Started Jan 2017; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03966079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966079.